CORT
HealthcareCorcept Therapeutics Incorporated · Biotechnology · $6B
What is Corcept Therapeutics Incorporated?
Corcept Therapeutics is a mid-cap specialty pharmaceutical company focused on cortisol modulation. Based in Menlo Park, California, it has built its commercial foundation around a single approved therapy while advancing a pipeline targeting serious metabolic and oncologic conditions.
Corcept discovers, develops, and commercializes drugs that modulate cortisol activity — a hormone implicated in a range of severe disorders. Its approved product, Korlym, generates the company's revenue by treating a specific form of Cushing's syndrome. Beyond Korlym, Corcept is advancing relacorilant, a selective cortisol modulator being studied in Cushing's syndrome and advanced ovarian cancer, alongside early-stage programs in prostate cancer and antipsychotic-induced weight gain.
Corcept Therapeutics was incorporated in 1998 and is headquartered in Menlo Park, California.
- Korlym (mifepristone) — approved oral therapy for Cushing's syndrome-related hyperglycemia
- Relacorilant — late-stage pipeline candidate for Cushing's syndrome
- Relacorilant plus nab-paclitaxel — combination therapy studied in advanced ovarian tumors
- Selective cortisol modulator programs in prostate cancer and metabolic disorders
- FKBP5 gene expression assays for cortisol pathway research
Is CORT a Good Stock to Buy?
UQS Score rates CORT as Good overall, reflecting a balanced profile with meaningful strengths and areas that warrant attention.
The Risk pillar stands out as the clearest positive — Corcept carries a financial profile that suggests resilience relative to many peers in the specialty pharma space. The Growth pillar also rates Good, supported by an expanding pipeline and the commercial trajectory of its approved product.
The Moat pillar is rated Weak, reflecting the competitive and regulatory pressures that single-product specialty pharma companies often face. The Quality and Valuation pillars both sit at Neutral, suggesting neither a clear discount nor a premium story at current levels.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CORT pay dividends?
No — Corcept Therapeutics Incorporated does not currently pay a dividend.
Corcept does not currently pay a dividend. For a company at this stage — with an approved commercial product and an active clinical pipeline — retaining capital to fund research, development, and potential label expansions is a common strategic choice. Income-focused investors should factor this into their assessment.
When does CORT report earnings?
Corcept Therapeutics reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Quarterly results tend to focus on Korlym revenue trends, pipeline milestones, and operating expense management. Investors typically watch for updates on relacorilant trial progress alongside commercial performance.
For the most recent quarter's results and upcoming reporting dates, visit Corcept Therapeutics' investor relations page directly.
CORT Price History
+108.8% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Corcept Therapeutics Incorporated?
Based on Corcept Therapeutics Incorporated's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CORT Long-term Outlook
Corcept's fundamental outlook is shaped by two dynamics: the durability of Korlym's commercial position and the potential of relacorilant to expand the company's addressable market. The Good Growth rating suggests the pipeline is viewed as a credible near-to-medium-term catalyst. However, the Weak Moat rating is a reminder that single-asset dependency and competitive threats in rare disease markets can limit long-term pricing power. The Strong Risk profile provides some reassurance that the balance sheet is positioned to weather development-stage uncertainty.
Growth drivers
- Relacorilant advancement toward potential regulatory approval in Cushing's syndrome
- Combination therapy data in ovarian cancer expanding the oncology opportunity
- Continued commercial execution behind Korlym in an underdiagnosed patient population
Key risks
- Single-product revenue concentration until pipeline assets reach commercialization
- Regulatory and clinical trial execution risk across multiple development programs
- Competitive pressure in the cortisol modulation and rare endocrine disorder space
CORT vs Peers
Corcept operates in a niche corner of specialty pharma alongside several smaller biotech companies targeting rare or underserved conditions.
Mirum focuses on rare liver diseases, giving it a distinct therapeutic focus compared to Corcept's cortisol-modulation platform.
Terns is a clinical-stage company developing therapies for metabolic and liver diseases, operating without a commercial product unlike Corcept.
Xenon targets ion channel biology for neurological disorders, representing a different scientific approach and disease area than Corcept's endocrine focus.
Frequently Asked Questions
What does Corcept Therapeutics do?
Corcept Therapeutics discovers and commercializes drugs that modulate cortisol, a hormone linked to serious metabolic, oncologic, and neuropsychiatric conditions. Its approved product, Korlym, treats hyperglycemia in adults with Cushing's syndrome. The company is also advancing a pipeline of selective cortisol modulators across multiple disease areas.
Does CORT pay dividends?
Corcept does not currently pay a dividend. The company retains its capital to fund ongoing clinical development and commercial operations, which is typical for specialty pharma companies with active pipelines.
When does CORT report earnings?
Corcept reports on a standard quarterly schedule. Exact dates are not available through our data source — check the investor relations section of Corcept's official website for the most current reporting calendar.
Is CORT a good stock to buy?
UQS Score rates CORT as Good overall. The Risk pillar is rated Strong and Growth is rated Good, but the Moat pillar is Weak and Quality and Valuation are both Neutral. Whether CORT fits your portfolio depends on your own risk tolerance and investment goals. The full pillar breakdown is available to Pro members.
Is CORT overvalued?
The UQS Valuation pillar for CORT is rated Neutral, suggesting the stock is neither clearly cheap nor obviously expensive relative to its fundamentals. Investors seeking a deeper view of the valuation metrics behind this rating can access the full analysis through a UQS Pro account.
How does CORT compare to its competitors?
Corcept stands apart from peers like Mirum Pharmaceuticals, Terns Pharmaceuticals, and Xenon Pharmaceuticals by having an approved, revenue-generating product in Korlym. Many comparable-sized specialty biotechs remain pre-commercial, which gives Corcept a different risk and revenue profile within the sector.
What is CORT's market cap bracket?
Corcept Therapeutics is classified as a mid-cap company. This places it above micro- and small-cap biotechs in terms of scale, while still being considerably smaller than large-cap pharmaceutical leaders in the healthcare sector.
Who founded Corcept Therapeutics?
Corcept Therapeutics was incorporated in 1998. Founding details are widely available through public company filings and the company's official history — the investor relations page is a reliable starting point for background information.
Is CORT a long-term quality stock?
As a long-term quality indicator, CORT's UQS profile shows a mixed picture. The Strong Risk rating and Good Growth rating are positives for durability, but the Weak Moat rating raises questions about competitive defensibility over time. Long-term investors should weigh pipeline execution risk alongside the commercial foundation Korlym provides.
What is the main competitive advantage of Corcept Therapeutics?
Corcept's primary advantage lies in its specialized expertise in cortisol modulation — a relatively narrow scientific niche — combined with an approved commercial product that generates revenue to fund further development. However, the UQS Moat pillar rates this advantage as Weak, reflecting the competitive and regulatory challenges common in specialty pharma.
What sector does CORT belong to?
Corcept Therapeutics operates in the Healthcare sector, specifically within specialty pharmaceuticals. It focuses on rare endocrine disorders and is expanding into oncology, placing it at the intersection of rare disease and targeted cancer therapy within the broader healthcare landscape.
Unlock Full CORT Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access detailed financial metrics behind each pillar
- ✓Compare CORT against sector peers side by side
- ✓Track pipeline and quality changes over time
- ✓Screen for similar mid-cap healthcare opportunities
Pro Analysis
CORT — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 46.2 | 31.3 | 29.0 | 69.1 | 63.4 | 51.9 | 0.0 |
| May 22, 2026 | 46.2 | 31.3 | 29.0 | 69.1 | 63.4 | 52.2 | -0.1 |
| May 21, 2026 | 46.3 | 31.3 | 29.0 | 69.1 | 63.4 | 52.6 | -0.1 |
| May 20, 2026 | 46.4 | 31.3 | 29.0 | 69.1 | 63.4 | 53.2 | -0.3 |
| May 19, 2026 | 46.7 | 31.3 | 29.0 | 69.1 | 63.4 | 55.4 | +0.1 |
| May 16, 2026 | 46.6 | 31.3 | 29.0 | 69.1 | 63.4 | 54.5 | +0.5 |
| May 15, 2026 | 46.1 | 31.3 | 29.0 | 69.1 | 63.4 | 51.1 | -0.1 |
| May 14, 2026 | 46.2 | 31.3 | 29.0 | 69.1 | 63.4 | 51.9 | -0.6 |
| May 13, 2026 | 46.8 | 31.3 | 29.0 | 69.1 | 63.4 | 56.0 | 0.0 |
| May 12, 2026 | 46.8 | 31.3 | 29.0 | 69.1 | 63.4 | 55.9 | +3.1 |
CORT — Pillar Breakdown
Quality
— 31.3/100 (25%)Corcept Therapeutics Incorporated currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 69.1/100 (20%)Corcept Therapeutics Incorporated demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 63.4/100 (15%)Corcept Therapeutics Incorporated maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 51.9/100 (15%)Corcept Therapeutics Incorporated has a mixed valuation — some metrics suggest fair value while others appear stretched.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Moat
— 29/100 (25%)Corcept Therapeutics Incorporated operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CORT.
Score Composition
Financial Data
More Stock Analysis
How is the CORT UQS Score Calculated?
The UQS (Unified Quality Score) for Corcept Therapeutics Incorporated is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Corcept Therapeutics Incorporated's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Corcept Therapeutics Incorporated is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.